The investigation of the clinical efficacy and effectiveness of Intensity Modulated Radiotherapy (IMRT) using Multileaf Collimators (MLC) and Helical Tomotherapy (HT) has been an issue of increasing interest over the past few years. In order to assess the suitability of a treatment plan, dosimetric criteria such as dose-volume histograms (DVH), maximum, minimum, mean, and standard deviation of the dose distribution are typically used. Nevertheless, the radiobiological parameters of the different tumors and normal tissues are often not taken into account. The use of the biologically effective uniform dose (D = ) together with the complication-free tumor control probability (P + ) were applied to evaluate the two radiation modalities. Two different clinical cases of brain and cranio-spinal axis cancers have been investigated by developing a linac MLC-based step-and-shoot IMRT plan and a Helical Tomotherapy plan. The treatment plans of the MLC-based IMRT were developed on the Philips treatment planning station using the Pinnacle 7.6 software release while the dedicated Tomotherapy treatment planning station was used for the HT plan. With the use of the P + index and the D = concept as the common prescription point, the different treatment plans were compared based on radiobiological measures. The tissue response probabilities were plotted against D = for a range of prescription doses.
Introduction
One of the major constraints in radiation therapy is the low tolerance doses characterizing the involved Organs-at-Risk (OAR). In treatments where these OARs are near the gross tumor volume (GTV) and the planning target volume (PTV), the possibilities for a suitable dose delivery are considerably reduced (1, 2) . It has been demonstrated that intensity modulated radiotherapy (IMRT) can produce better results than conventional and simple conformal radiation therapy techniques, due to a significant reduction of radiation dose and toxicity delivered to the critical organs (3) . Today, several treatment planning systems (TPS) can perform physical IMRT optimization. Helical Tomotherapy (HT) is a technology for radiation therapy, characterized by dose distributions of higher dose conformality compared to other IMRT techniques (4, 5) . In HT technology, radiation dose is delivered helically through fifty-one projections per rotation. Reports on the physical comparison of dose distributions delivered by 3D-Conformal and IMRT techniques have been published recently (6, 7). However, the use of radiobiological measures in comparison studies of the effectiveness of dose distributions between HT and other IMRT modalities, including linac-based IMRT using a multileaf collimator (MLC) in a step-and-shoot mode, are very limited. Consequently, the question regarding the comparison of the effectiveness of the corresponding treatment modalities and the need for a change in the treatment methodology still remains. It has to be noted that since Tomotherapy is a rotational therapy technique and standard IMRT is a fixed-gantry technique, it would be interesting to extend the present analysis for the cases of linac-based intensity-modulated arc therapy techniques such as Rapid Arc (Varian and UBC), arc-modulated radiation (U. Maryland), and VMAT (Elekta).
The selection of the best plan can be a challenging task due to the variations in the optimization methodology, which may lead to significant discrepancies between the integral doses and the expected response probabilities. The dose volume histogram (DVH), the maximum, minimum, mean, and standard deviation of a dose distribution, are mainly the criteria used for radiotherapy treatment plan evaluation. Nevertheless, all the above evaluation factors do not account for the radiobiological characteristics of the tumors or normal tissues involved. In some situations, competing plans are characterized by significant disrepancies in radiobiological outcomes even though they have similar mean, maximum, and minimum doses (8) . In order to deal with such cases, the use of the biologically effective uniform dose (D = ) and complicationfree tumor control (P + ) have been employed for radiotherapy treatment plan evaluation (9). The biologically effective uniform dose, D = is a concept assuming that different dose distributions are equivalent when causing the same probability for tumor control or normal tissue complication (8) .
The aim of this study is to use radiobiological measures for comparison of the MLC-based IMRT and HT radiation modalities in brain and cranio-spinal cancer radiotherapy. To achieve this goal, two treatment plans have been developed using the Philips (ADAC) Pinnacle treatment planning system (TPS) and two plans using an HT TPS. The maximum, the minimum, and the mean doses were calculated while the P + index and the dose D = were derived and analyzed (10) (11) (12) (13) (14) .
Material and Methods
In this study, the clinical cases of a brain cancer and a craniospinal axis cancer were investigated. For the final approval of the different treatment configurations, the following clinical criteria were used: (i) uniform dose to the PTV (standard deviation less than 5%), (ii) minimum dose to the surrounding healthy tissue stroma, and, (iii) minimum dose to the OARs (below their respective tolerance dose). The basic characteristics of the two clinical cases are presented below.
Brain Cancer Case
A 57-year-old male with recurrent hemangiopericytoma of the brain was treated to 54 Gy in 30 fractions. There are two couch angles. For couch angle 180, the gantry angle was set to 0, 130, 80, 30 degree; for couch angle 270, the gantry angle was set to 90, 115, 60 degree. Photon beam energy was 6 MV.
Cranio-spinal Axis Cancer Case
A 15-year-old male with medulloblastoma was treated to the cranio-spinal axis to 40 Gy in 20 fractions. The patient's plan developed by Pinnacle 3 was complex. There were three isocenters: one was for the brain, one was for the upper spine, and one was for the lower spine. The brain was treated with IMRT beams and the spine was treated with IMRT plus 3D conventional beams. Two beams were set for the brain PTV and the couch angles were 187.4 degree with gantry angle 270 degree and couch angle 172.4 degree with gantry angle 90. Photon beam energy was 6 MV. Six spine beams were set for the spine PTV (three for the upper spine and three for the lower spine). Photon beam energy was 18 MV for the spine beams. Couch angle was set 180 and gantry angles were 0, 315, 45 degree for the upper and lower parts of the spine, respectively. The 0 degree gantry angle beam was IMRT beam and the 315 and 45 degree beams were 3D conventional beams.
For each clinical case, four additional patients were examined in order to investigate if the results of the present analysis are more general. All calculations were performed using the convolution/superposition dose calculation algorithm, which accounts for density inhomogeneity effects (15, 16) .
Treatment Planning and Respective Treatment Modalities
The two treatment delivery machines used for the linac MLC-based step-and-shoot IMRT plan and the HT plan are: a Varian linac 21EX with a dose calculation grid resolution of 3 × 3 × 3 mm 3 (Varian medical systems, Palo Alto, CA) and a Hi×Art II TomoTherapy (TomoTherapy, Inc. Madison, WI). The Varian linear accelerator model was a 21EX outfitted with a MILLENNIUM 120 leaf MLC. The HT plan was helicaly delivered from 51 beam angles per rotation. In order to achieve the prescribed objectives, it is required to produce the sinogram intensity modulation. The 2.5 × 40 cm 2 slit beam was modulated by a binary 64 leaf collimator. Α Pinnacle (ADAC Laboratories, Milpitas, CA version 7.6c), treatment planning system was used for the MLCbased IMRT linear accelerator plans. A dedicated Tomotherapy treatment planning station, version 2.1.2, was used for the HT plans. The delineation of the targets and OARs was performed on the Pinnacle planning station and this information was subsequently transferred to the Tomotherapy planning station using the DICOM-RT protocol.
A CT simulation was performed by setting the patient in the treatment position using rigid immobilization devices. The planning target volumes (PTV) were created by expanding the gross tumor volumes (GTV) with an appropriate margin (1 cm) for organ motion and patient setup uncertainties. In the case of the cranio-spinal cancer in certain occasions this margin was increased to 2 cm when the incoming beam and the associated direction of organ motion were perpendicular. In the end of the HT treatment planning process, the dose matrix was exported to the Pinnacle workstation for comparative analysis and evaluation. The export of the dose matrix from the Tomotherapy TPS and its transfer to the Pinnacle planning station was performed through an in-house developed software tool, which assures the correct alignment and scale of the dose matrix with the patient's anatomy (17). The treatment plan of Helical Tomotherapy used normal dose calculation grid, which is 2 voxels × 2 voxels × 1 slice width. Since the original CT images were down-sampled once by Tomotherapy treatment planning system, the dose calculation grids for Helical Tomotherapy were 4mm × 4mm × 3mm. For Pinnacle treatment plans, the dose grids were 3mm × 3mm × 3mm. This small difference in the dose grid resolution of the Helical Tomotherapy and the IMRT plans did not seem to affect the values of dosimetric measures (e.g., D max and D min ) since their volumes are comprised by several voxels.
The linac-based step-and-shoot IMRT plan was optimized with direct machine parameter optimization (DMPO). In the HT treatment plan optimization, the initial setup was performed using a special protocol. The jaw setting was selected as 2.5 cm, with the pitch value set to 0.287, and the modulation factor was set to 2.0 for these treatment sites. For tumors, the importance value was set to 50, while the maximum and minimum dose penalties were set to 100. For the organs at risk, the importance value was set to 15, while the maximum dose and DVH point penalties were set to 1 and 20, respectively. After the completion of the optimization, the same physician reviewed the dose-volume histograms and the isodose distributions for final approval of the treatment plans.
Radiobiological Treatment Plan Evaluation
The dose-response relation of tumors and normal tissues is described by the Poisson model (18, 19) , expressed by the following equation:
where P(D) is the probability to control the tumor or induce a certain injury to a normal tissue that is irradiated uniformly with a dose D. D 50 is the dose which gives a 50% response and γ is the maximum normalized dose-response gradient. The values of the D 50 and γ parameters depend on the organ and type of clinical endpoint and they are regularly derived from clinical data (13, 14, (20) (21) (22) . The dose distributions had to be corrected for the fractionation effects, hence the use of the relevant α/β ratios, were necessary. The organ response to a non-uniform dose distribution is derived from an expanded version of Eq.
[1] for tumors while the response of a normal tissue can be calculated by the relative seriality model, which accounts for the volume effect (19, 22) . According to this model, the overall probability of injury, P 1 for a number of OARs, is expressed by the equation:
where N organs is the total number of vital OARs. P j (D i ) is the probability of response of the organ j having the reference volume and being irradiated to dose D i as described by Eq.
[1]. Δv i = ΔV i /V ref is the fractional subvolume of the organ that is irradiated compared to the reference volume for which the values of D 50 and γ have been calculated. M j is the total number of voxels or subvolumes in the organ j, and s j is the relative seriality parameter characterizing the internal organ structure j. The value s ≈ 1 corresponds to a serial structure whereas s ≈ 0 corresponds to a parallel structure. It should be mentioned that other models such as the LKB (23-26) could also be used, selecting the appropriate response parameter sets.
The structural organization in tumors, is assumed to be parallel since the eradication of all their clonogenic cells is required. Moreover, the eradication of every individual tumor has to be achieved in complex multi-target cancer cases. This pattern indicates that the different targets are related through a parallel organization fashion. Hence, the overall probability of benefit P B , is given by the expression:
where N tumors is the total number of tumors or targets involved in the clinical case.
Tables I and II, present the dose-response parameters of the organs together with the clinical endpoint to which they refer. The parameter set is based on published data (11-14, 20, 21, 27-30) . The uncertainties associated with these parameters are of the order of 5% for D 50 , 30% for γ, and 90% for s, defining the confidence interval of the entire dose-response curve around its best estimate (31). Our study assumes that the patients are of average radiosensitivity, thus characterized by the mean estimates of the presented radiobiological parameters.
The effectiveness of the different treatment plans is evaluated though the concepts of the biologically effective uniform dose, D = and P + , which expresses the probability of achieving tumor control without causing severe damage to normal tissues (9). In this study, the probability of getting benefit from a treatment (tumor control) is denoted by P B , whereas the probability for causing severe injury to normal tissues is denoted by P 1 (3, 22) . Therefore, P + can be estimated from the following equation (18):
where P B∩I is the probability of achieving tumor control and simultaneously having severe healthy tissues damage. In this study, the D = concept is additionally used together with other dosimetric quantities to evaluate the treatment plans. The biologically effective uniform dose is defined as the dose that causes the same tumor control or normal tissue complication probability as the actual dose distribution given to the patient (8). In the former case the biologically effective uniform dose is denoted as D = B whereas in the latter case as D = I The notation D = indicates that the quantity has been averaged over both the dosimetric (dose distribution) and the biological (dose-response relations) information of the clinical case. The general expression of D = for a given tumor or normal tissue does not depend on the applied radiobiological model. For the Poisson model and a tissue of uniform radiosensitivity, D = is derived from the following analytical formula:
where D → denotes the 3-dimensional dose distribution (8). A number of plan trials can be compared based on radiobiological endpoints using this concept, by normalizing their dose distributions to a common prescription point (D = ) and plot-ting the tissue response probability versus D = .
The treatment plans of the study were radiobiologically evaluated using the radiation sensitivities of the tumors and the OARs involved, although conventional physical criteria like dose volume histograms, isodose charts, et cetera, were also employed (32, 33).
Results
Figures 1 and 2 illustrate the comparison of the isodose curve distributions of the HT and MLC-based IMRT treatment plans respectively, in transverse, coronal, and sagittal views. The isodose curves are shown in different views in order to better illustrate the differences between the HT and MLC-based IMRT treatment plans. In Figures 3 and 4 , the treatment plans are compared in terms of DVHs and dose-response curves for the cancer types of brain and cranio-spinal axis, respectively. The dose-response curves of each target and OAR are presented, together with the P + curve. In the upper right diagrams of the Figures 3 and 4 , the response curves are all normalized to the mean dose in the PTV (D -PTV ). In the lower left diagrams of the figures, the dose-response curves have been normalized to the D = B , which forces the response curves of the PTV (P B ) of the two treatment plans to coincide. Finally, in the lower right diagrams of the figures, the dose-response curves have been normalized to the D = I , which forces the total complication response curves (P I ) of the two treatment plans to coincide. In these diagrams the same dose distribution is kept at all dose levels and the curves show how tissue responses change with dose prescription. The normalization using D = B or D = I allows the inter-comparison of the different modalities on the same basis and gives emphasis to the therapeutic window, which characterizes each treatment plan. The dose-response parameters of the organs were used to estimate the normal tissue tolerance and the optimum target dose needed. In Tables III and IV, a quantitative summary of the physical and biological comparisons is presented.
Brain Cancer Case
In this clinical case of brain cancer, the sensitive OARs are the brain, chiasma, eyes, optical nerves, and speech area. Based on the isodose curves distribution, it appears that both radiation modalities have similar dose spread outside the PTV. For the HT and MLC-based IMRT radiation modalities, the planned mean doses to the brain, the left optical nerve, the right eye, and the speech area are very similar (Table III) . However, the HT delivers a higher dose to the chiasma, the left eye and right optical nerve compared to the MLC-based IMRT (9.1Gy vs 6.2Gy, 11.8Gy vs 2.0Gy, and 6.5Gy vs 4.3Gy, respectively). In both cases, the mean dose, D to the PTV is almost equal to the corresponding D = values owing to the very small dose variations within the PTV. On the contrary, the dose distributions within the OARs are characterized by larger variations, which are similar for the two [3] [5] Biological Comparison of Helical Tomotherapy and MLC-based IMRT Treatment Plans 7 radiation modalities. This has as a consequence that the D = values of the normal tissues are greater than the corresponding mean dose values (D -). By using the Non-Tumor Integral Dose (NTID) concept, it was calculated that the MLC-based IMRT plan delivers 1.79 times higher dose to the normal tissue of the patient than the HT plan (142.77 vs 79.71 Gy-Kg).
For this dose prescription the P + value is 37.9% for HT for a biologically effective uniform dose to the PTV, D = B of 53.6 Gy. The total control probability P B is 38.6% and the total complication probability P I is 0.7%, which is equal to the response probability of the speech area. Similarly, for the MLC-based radiation modality the P + value is 40.0% for a D = B of 54.0 Gy. The total control probability P B is 40.9% and the total complication probability P I is 0.9%, which mainly stems from the probability of the speech area injury. However, if we optimize the dose level in order to maximize the complication-free tumor control, the P + value becomes 66.1% for a D = B of 63.0 Gy with P B = 79.5% and P I = 13.4% for HT. For the MLC-based IMRT the maximum P + value is 63.5% for a D = B of 62.0 Gy with P B = 76.6% and P I = 13.1%. A more qualitative description of the treatment plan evaluation is presented in the upper left diagram of Figure 3 . It is shown that the treatment plans are very conformal and both HT and MLC-based IMRT satisfy the plan objectives. The primary OARs are spared very well apart from the speech area, which is located very close to the PTV. At the prescribed dose level of the distribution, the mean doses to the targets are high (53.6 and 54.0 Gy, respectively) but not to the optimum level (63.0 and 62.0 Gy, respectively), which would maximize their control rates while increasing the expected complications from 0.9% to 13.0%. With the exception of the speech area, the mean and maximum doses in the OARs are low ensuring low levels of expected complications. For the speech area, the high maximum doses appear to be elevated (64.2 and 62.0 Gy, respectively), which is attributed to part of the organ, which is located in the high dose gradient area at the borders proximal to the PTV.
Cranio-spinal Axis Cancer Case
In this clinical case of cranio-spinal cancer, the sensitive OARs are the lung, spinal cord, healthy tissue, heart, liver, kidneys, eyes, and optical nerves. Based on the isodose curve distributions, it is clear that the HT plan has lower dose spread outside the PTV and lower inhomogeneity inside the PTV. For the HT radiation modality, the mean dose to the PTV is a little higher (47.9Gy vs 44.0Gy and 52.9Gy vs 46.4Gy) compared to the MLC-based IMRT (Table IV) . Regarding the OARs, the MLC-based IMRT delivers higher mean doses to the lung, left and right kidneys, left and right eyes, left and right optical nerves compared to the HT plan, whereas the HT delivered higher doses to the spinal cord and healthy tissue stroma (see Table IV ). In all cases, the mean dose, D to 
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the PTV is very close to the corresponding D = values owing to the small dose variations within the PTV. On the contrary, the dose distributions within the OARs are characterized by quite larger variations with the largest ones being observed in the MLC-based IMRT plan. This has as a consequence that the D = values of the normal tissues are greater than the corresponding mean dose values (D -), especially for the healthy tissue stroma and left and right eyes. By calculating the NTID values, it was calculated that the MLC-based IMRT plan delivers 1.29 times higher dose to the normal tissue of the patient than the HT plan (3514.05 vs 2725.35 Gy-Kg).
For the optimum dose prescription the P + value for the HT plan is 84.1% for a mean dose to the PTV of D -PTV = 64.3 Gy and biologically effective uniform dose to the PTV, D = B of 50.6 Gy. The total control probability P B is 86.4% and the total complication probability P I is 2.3%. Similarly, for the MLC-based radiation modality the P + value is 28.3% for D -PTV = 62.4 Gy and D = B of 44.0 Gy. The total control probability P B is 51.3% and the total complication probability P I is 23.0%. In this case, the clinical dose prescription, which is associated with a complication rate less than 5% in the 3D-conformal and IMRT treatments was applied to the HT plan initially. However, it is obvious that this dose prescription is far from the optimum since the HT dose distribution conforms much better to the demands of the clinical case. A more qualitative description of the treatment plan evaluation is presented in upper diagram of Figure 4a . It is shown that HT is characterized by a higher dose conformality to the PTV than MLC-based IMRT. At the same time, it spares most of the OARs involved. At the prescribed dose level, the mean doses to the PTV are high but not close to the optimum level, which would maximize their control with a good compromise for the complications. With the exception of the left kidney and lung for the MLC-based IMRT, the mean and maximum doses in the organs at risk are low ensuring low levels of expected complications. For the left kidney and lung, the high maximum dose values are due to their proximity to the PTV.
Discussion
Up-to-date, only a few studies have been carried out regarding comparisons of HT against MLC-based IMRT (34), especially regarding brain and cranio-spinal axis tumors. However, these studies performed only dosimetric comparisons between these two radiation modalities without examining the impact of the observed differences on the expected treatment outcome. Our study aims to cover this important gap in the assessment of the clinical effectiveness of these modalities, by interpreting the dosimetric characteristics of the four different treatment plans into expected rates of tumor control and normal tissue complications.
In order to evaluate the clinical effectiveness of MLC-based IMRT and Helical Tomotherapy, the dose distribution uniformity in the target volume and the dose level constraints are usually defined as the evaluation and classification parameters of the different radiation modalities. In Figure 1 , it is seen that the MLC-based IMRT and HT plans, covered sufficiently well the PTV with the prescribed dose. However, the involved OARs are spared better with the HT compared to the MLC-based IMRT, in both clinical cases. The results show that HT and MLC-based IMRT may produce dose distributions with fairly homogeneous doses to the PTV and small integral doses to the healthy organs.
The differences observed on the DVHs comparing the MLCbased IMRT and HT treatment plans, are not always reflected in the radiobiological evaluation. This is due to the fact that the different tissues respond in different ways to a certain dose distribution. In this sense, two dose distributions irradiating the same tissue, may have equal values of mean dose and standard deviation, but different response probabilities. The lower left diagrams of Figure 3 and left diagram of Figure 4b , where the D = B is used, show a coincidence of the curves corresponding to the response of the PTV (P B ). In this way, the classification and the superiority of the plans are determined by comparing the response curves of the OARs. Similarly, the D = I is used as the dose level reference in the corresponding right diagrams. In this case, the curves corresponding to the total complication probability, P I lie at the same position for the different plans and the classification and superiority of the plans are determined by comparing the tumor control (P B ) curves. By using diagrams of this type, it is easier to observe how the control probability changes, when certain complication thresholds are examined. The D = concept is based on the assumption that a 3-dimensional dose distribution may be reduced to a single dose, causing the same response probability. The use of the PTV mean dose, does not provide a common base of dose scaling in order to compare different plans and this is due to the fact that for the same control rate, different mean doses to the PTV are delivered by different plans. Furthermore, it is harder to compare the effect of the treatment to the residual involved organs using this scale (Figures 3 and 4a, upper diagrams) .
As it is shown in Figures 3 and 4 , the expected complication-free tumor control for the HT treatment plans is better compared to that of the MLC-based IMRT plans over the whole range of clinical prescribed doses. The explanation is that the HT plans irradiate the PTV more effectively than the MLC-based IMRT dose distributions while it achieves similar sparing of the speech area in the brain cancer case and much better sparing of most of the OARs in the craniospinal cancer case, as shown in Tables III and IV. The individual DVHs and dose-response curves of all the tissues are illustrated in Figures 3 and 4 . It is important to mention that although the HT plan delivers lower mean dose to the speech area it shows a higher complication probability compared to the MLC-based IMRT due to the higher maximum dose and its high relative seriality value. Higher mean doses to the lung and left kidney, which are parallel organs (characterized by low relative seriality values), are delivered by the MLC-based IMRT plan and this is the dominating factor for the large complication probabilities (8.1% and 14.2% vs 1.7% and ~0.0, respectively). In this case, although the dose variation is large, the D = value does not deviate much from the corresponding mean dose, D due to the low relative seriality values characterizing these tissues. As far as tissues of parallel internal organizations are concerned, dose inhomogeneity does not affect so much their response, which is mainly determined by the mean dose. Figure 4b , the clinically established dose prescription, corresponding to a certain uniform dose in the PTV, deviates from the optimal dose level that the radiobiological evaluation gives for the two clinical cases. In Tables III and IV, it is observed that in the case of the MLC-based IMRT plan, the clinical dose prescription lies below the optimum and this is due to the acceptable compromise been achieved. Nevertheless, when the radiobiological data of the different tissues are applied, a margin of improvement is indicated. With a small increase in the dose prescription, the gain in tumor control is larger than the increment in normal tissue complications until a balance is reached. In the brain cancer case, the clinical dose prescription is lower than the optimum dose level by a ΔD = of -9.4 Gy for the HT plan and -8.0 Gy for the MLCbased IMRT plan, whereas in the cranio-spinal axis cancer case, the ΔD = is -12.3 Gy for the HT plan and -5.6 Gy for the MLC-based IMRT plan. This is because a quite high risk for normal tissue complications had to be accepted in order to ensure a high tumor control probability.
In the lower left diagrams of Figures 3 and left diagram of
In the DVH diagrams (Figure 3 , upper left and Figure 4a , upper), a significantly increased dose to the more radioresistant PTV is observed. For the HT plans, the OARs receive quite low doses and their response curves are well separated from the targets. This broadens the therapeutic window of the treatment leading to a better expected clinical outcome as it is shown in the lower diagrams of Figure 3 and diagrams of Figure 4b . It can also be seen that the width of the therapeutic window broadens with the height of the curve of P + (35). Therefore, the width of the P + curve expresses the separation between the response curves of the tumors and the healthy tissues involved. The width of the therapeutic window gives also an indication of how robust the treatment plan is against the dose delivery and patient radiosensitivity uncertainties. At the same time, the optimum treatment modality is indicated, since the most conformal treatment plan generates a higher value of P + . Apart from just optimizing physical functions, the use of this method takes into account the radiobiological characteristics of the given clinical case.
It has been shown that radiation doses to OARs can be significantly limited when using IMRT. Nevertheless, when CTV is adjacent to highly radiosensitive critical organs, the PTV expansion often does not allow for sparing parts of that organ. A preferential OAR sparing allows a margin expansion of the GTV and CTV as well as it expands the possibilities for dose escalation. Dose inhomogeneity can be viewed as a concurrent radiation local boost, giving a higher total radiation dose to a limited region (36). Even though a very accurate setup can be provided taking a CT immediately before each treatment fraction, organ motion normally is not taken into account during a treatment session (37-39). The amount of movement during quiet respiration might be assumed to be less than during full inspiration and expiration, but the little number of studies published present discrepancies between their results. During quiet respiration, the amount of movement in the cranio-caudal axis may reach 20 mm (40).
A key point of this study is the usefulness of P -D = diagrams (Figures 3 and 4b) . These diagrams combine the dosimetric information of the delivered dose distribution with the radiobiological information of the organs involved. In the definition of the P + concept, it would be more reasonable if the different terms related to the tumor control and normal tissue complication probabilities were accompanied by some weighting factors, which could be clinically adjusted. With the use of the D = concept on the dose axis, the control and complication probabilities regarding the different targets and OARs can be individually examined. The major advantage is that the D = concept forces the total control or total complication probabilities of different plans to coincide.
The results of this study depend strongly on the accuracy of the radiobiological models and the parameters describing the dose-response relations of the different tumors and normal tissues. Furthermore, the determination of the model parameters expressing the effective radiosensitivity of the tissues is subject to the uncertainties imposed by inaccuracies in the patient setup during radiotherapy, the lack of knowledge of the inter-patient and intra-patient radiosensitivity and the inconsistencies in treatment methodology (41) (42) (43) . Consequently, the determined model parameters (such as the D 50 , γ, and s) and the corresponding dose-response curves have their respective confidence intervals.
In the present study, most of the tissue response parameters have been taken from recently published clinical studies, where the confidence intervals have been significantly reduced (e.g., uncertainty of around 5% in the determination of D 50 ). Therefore, in many cancer sites the expected response of a tissue may be known with a clinically acceptable uncertainty. This uncertainty does not affect the principal conclusions of the study.
Given that one case per treatment site was evaluated in this study, a statistically significant sample of cases would give a more accurate picture of the comparisons. By examining four additional patients, the observations of the present analysis were confirmed. This was expected since the eight treatment plans (four for each treatment modality) were produced using the same predefined criteria (inverse optimization). So, even if one typical case is examined in detail, the ability of a certain radiation modality to conform dose distribution can be validated. Thus, although a strict inter-modality comparison cannot be performed, an indication of the effectiveness of the two radiation modalities can be given. Both the MLCbased IMRT and HT modalities appear to have similar possibilities in producing highly conformal dose distributions when treating regular sized targets. Possibly, the very large number of degrees-of-freedom characterizing the radiobiologically guided IMRTs makes it difficult to find a clear difference between them (44). However, in the irradiation of large sized targets (larger than 40 cm length), the potentially superior radiobiological results of the HT compared to the MLC-based IMRT modality could be clearly demonstrated. Furthermore, the findings of this study show that the (P -D = ) diagrams, can be considered as the radiobiological version of the extensively used DVH diagrams.
It has to be mentioned that the present comparison may be interesting to extend to other linac-based intensity-modulated arc therapy techniques such as Rapid Arc (Varian and UBC), arc-modulated radiation (U. Maryland) and VMAT (Elekta) (45-47). The disadvantage of gantry-fixed IMRT technique is apparent in the cranio-spinal case, where the doses to the critical structures are much higher in the MLC-based IMRT plans than the HT plans. This is because one of the challenges of gantry-fixed IMRT is the beam angle selection. The beam angle selection is never a problem in rotational therapy where all the beam angles are used. The comparison between the standard gantry-fixed IMRT and Helical Tomo-therapy was chosen because arc therapy is just getting into clinic while fixed gantry IMRT is still widely used. We plan to investigate the current state of the art regarding the clinical effectiveness of Helical Tomotherapy compared to recent arc therapy techniques with a similar analysis.
Conclusion
The clinical effectiveness of Helical Tomotherapy and MLC-based IMRT was evaluated for brain and cranio-spinal cancer cases. Using both physical and biological criteria, this evaluation showed that the HT radiation modality produced better expected clinical outcomes as compared to the MLC-based IMRT plans. Treatment plans delivering low integral doses to the healthy tissues and fairly homogeneous doses to the PTV can be produced by HT and MLC-based IMRT radiation modalities for treating regular sized targets, whereas in the treatment of large sized targets the effectiveness of HT is significantly superior.
The therapeutic indices P + and D = can be used as figures of merit for a treatment plan and their use may increase the probability to accomplish a good treatment result. A radiological treatment plan provides a closer relation of the treatment delivered with the clinical outcome since it combines the dose distribution with the radiosensitivity map of the patient. For a clinically relevant quantification of a dose distribution the use of radiobiological parameters is necessary. The application of the P + and D = concepts on the representative MLCbased IMRT and HT treatment plans revealed differences in the expected therapeutic impact of the two radiation modalities. The use of P -D = diagrams can compliment the traditional tools of evaluation such as DVHs, in order to compare and effectively evaluate different treatment plans.
